KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Income: 2009-2025

Historic Net Income for Halozyme Therapeutics (HALO) over the last 17 years, with Sep 2025 value amounting to $175.2 million.

  • Halozyme Therapeutics' Net Income rose 27.89% to $175.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $595.5 million, marking a year-over-year increase of 51.72%. This contributed to the annual value of $444.1 million for FY2024, which is 57.71% up from last year.
  • As of Q3 2025, Halozyme Therapeutics' Net Income stood at $175.2 million, which was up 6.11% from $165.1 million recorded in Q2 2025.
  • Over the past 5 years, Halozyme Therapeutics' Net Income peaked at $216.6 million during Q3 2021, and registered a low of $22.7 million during Q2 2022.
  • In the last 3 years, Halozyme Therapeutics' Net Income had a median value of $93.2 million in 2024 and averaged $107.6 million.
  • Its Net Income has fluctuated over the past 5 years, first skyrocketed by 557.07% in 2021, then tumbled by 75.20% in 2022.
  • Halozyme Therapeutics' Net Income (Quarterly) stood at $66.8 million in 2021, then decreased by 13.58% to $57.7 million in 2022, then soared by 47.98% to $85.4 million in 2023, then surged by 60.46% to $137.0 million in 2024, then increased by 27.89% to $175.2 million in 2025.
  • Its last three reported values are $175.2 million in Q3 2025, $165.1 million for Q2 2025, and $118.1 million during Q1 2025.